Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant extension study in pediatric migraine
NCT05127954Phase 3Enrolling by invitation
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of ubrogepant in migraine (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Adverse Events (AEs) up to 54 weeks, Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG) up to 54 weeks and 6 more. Started Jan 2022; status: enrolling by invitation.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05127954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127954.